Counterpoint: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?

In this Point/Counterpoint, Drs. Madueke and Abern argue that active surveillance should not currently be considered for patients with intermediate-risk prostate cancer.

Source: CancerNetwork - June 19, 2019 Category: Cancer & Oncology Authors: Ikenna Madueke, MD, PhD, Michael R. Abern, MD Source Type: news